A01K 2217/15
Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination
Official title: Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
A01K2217/15 (Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination) appears on 490 US grants and 1,026 published applications in this corpus.
Search patents in A01K- Granted patents
- 490
- Published applications
- 1,026
- Assignees
- 354
- Inventors
- 1,398
- Latest grant
- 1 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2002 | 1 | 1 |
| 2003 | 0 | 2 |
| 2004 | 0 | 1 |
| 2005 | 0 | 2 |
| 2006 | 1 | 7 |
| 2007 | 0 | 1 |
| 2008 | 3 | 8 |
| 2009 | 5 | 11 |
| 2010 | 2 | 23 |
| 2011 | 6 | 37 |
| 2012 | 5 | 35 |
| 2013 | 10 | 53 |
| 2014 | 17 | 47 |
| 2015 | 40 | 63 |
| 2016 | 29 | 71 |
| 2017 | 33 | 55 |
| 2018 | 46 | 69 |
| 2019 | 34 | 84 |
| 2020 | 33 | 76 |
| 2021 | 52 | 76 |
| 2022 | 30 | 74 |
| 2023 | 37 | 53 |
| 2024 | 44 | 75 |
| 2025 | 39 | 61 |
| 2026 | 23 | 41 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Methods of treating mitochondrial disorders1 Sep 2026US 12,723,062 B2The Regents of the University of California
- Neurodegenerative and amyotrophic model animal25 Aug 2026US 12,714,076 B2Tokyo Metropolitan Institute of Medical Science
- Multi-transgenic pig for Xenotransplantation25 Aug 2026US 12,714,077 B2Revivicor, Inc.
- Pharmaceutical composition for treating degenerative brain disease, including glycine transporter as active ingredient18 Aug 2026US 12,708,657 B2Amyloid Solution Inc.
- Genetically modified non-human animals expressing human EPO4 Aug 2026US 12,696,884 B2Institute for Research in Biomedicine (IRB)
- Genetically Modified Non-Human Animals and Methods of Use Thereof8 Oct 2026US 2026/0305588 A1Institute for Research in Biomedicine (IRB)
- Methods and compositions for insertion of antibody coding sequences into a safe harbor locus1 Oct 2026US 2026/0297613 A1Regeneron Pharmaceuticals, Inc.
- A method for detecting protein targets of an enzyme using a biotin ligase20 Aug 2026US 2026/0243776 A1Leibniz-Institut Fur Alternsforschung—Fritz-Lipmann-Institut E.V. (Fli)
- Non-Human Animals Expressing Humanized CD3 Complex13 Aug 2026US 2026/0231915 A1Regeneron Pharmaceuticals, Inc.
- Methods for modifying a genome13 Aug 2026US 2026/0234672 A1Regeneron Pharmaceuticals, Inc.
Most cited
By later US patents
- Transgenic transchromosomal rodents for making human antibodies195US 7,041,870 B2Kirin Brewery Co., Ltd. · 2006
- Transgenic animals bearing human Igλ light chain genes134US 7,435,871 B2Amgen Fremont Inc. · 2008
- ADAM6 mice83US 8,642,835 B2Regeneron Pharmaceuticals, Inc. · 2014
- ADAM6 mice75US 8,697,940 B2Regeneron Pharmaceuticals, Inc. · 2014
- Genetically modified mice having humanized TCR variable genes50US 9,113,616 B2Regeneron Pharmaceuticals, Inc. · 2015